Loading…
Loading…
DiaSorin S.p.A. (DSRLF) Q2 2026 Earnings Call Transcript
DiaSorin S.p.A. (DSRLF) Q1 2026 Earnings Call Transcript
DiaSorin (OTCMKTS:DSRLF - Get Free Report) and Perrigo (NYSE: PRGO - Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Analyst Ratings This is a summary of current ratings and
DiaSorin S.p.A. (DSRLF) Q4 2025 Earnings Call Transcript
DiaSorin (OTCMKTS:DSRLF - Get Free Report) and Abbott Laboratories (NYSE: ABT - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends. Risk and Volatility DiaSorin has a beta of 0.1,
DiaSorin (OTCMKTS:DSRLF - Get Free Report) and IM Cannabis (NASDAQ: IMCC - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability. Risk and Volatility DiaSorin has a beta of 0.12,
Invesco International Small-Mid Company Fund added six new positions and exited 11 positions during the quarter. We are benchmark independent, bottom-up investors, focusing on company fundamentals rather than using a “top-down” perspective to overweight or underweight any sector or region. We exited AIA Engineering, Belimo, Epiroc, Japan Elevator Service, Kardex, Konami, and Triveni Turbine.
DiaSorin's 2024 revenue grew by 3%, with an underlying increase of 7%, and net profit rose to 188.1M EUR, reflecting a 17% EPS increase. The company generated strong free cash flow of 191M EUR, enabling potential M&A activities to support future growth. DiaSorin's 2025 guidance targets a 7% revenue increase and a 34% adjusted EBITDA margin, with plans to reach a 36-37% margin by 2027.
No recent filings indexed.